Joy A. Amundson is a corporate vice president of Baxter Healthcare Corporation and president of the company s BioScience business. In this position, she is responsible for the development and worldwide marketing of Baxter s biopharmaceutical, vaccine and biosurgery products. Prior to joining Baxter in 2004, Ms. Amundson was a principal of Amundson Partners, Inc., a healthcare consulting firm. She also served in a variety of executive positions at Abbott Laboratories for more than 20 years, including as president of that company s Ross Products division. Ms. Amundson also served in several sales and brand management roles during a six-year tenure at Procter & Gamble. Ms. Amundson is a member of the board of directors of specialty medical device company INAMED Corp.; biopharmaceuticals company ILEX, Inc., and Advocate Lutheran General Hospital in suburban Chicago. She holds a bachelor of arts degree in journalism and advertising from the University of Wisconsin and a master s of management degree from Northwestern University s Kellogg Graduate School of Business. Peter J. Arduini is a corporate vice president of Baxter Healthcare Corporation and president of the company's Medication Delivery business, a leader in the development and manufacturing of a wide range of products focused on delivering critical fluids and drugs to patients. Prior to joining Baxter in March 2005, Mr. Arduini worked for General Electric Healthcare, where he spent much of his 15 years in a variety of management roles for domestic and global businesses. In addition to having served in sales management, Mr. Arduini also oversaw marketing, market research, product design and engineering program development for its radiology and cardiology franchise. His last role with General Electric Healthcare was as global general manager of its cat scan (CT) and functional imaging business, a $2 billion capital equipment and innovation-intensive business. Prior to joining General Electric Healthcare, Mr. Arduini spent four years with Procter & Gamble. Mr. Arduini received his bachelor s degree in marketing from Susquehanna University and a master s in management from Northwestern University s Kellogg School of Management. Kenneth E. Burhop, Ph.D., is vice president and global scientific lead for Baxter s Medication Delivery business. Dr. Burhop joined Baxter in 1986. From 1990 to 2003, he assumed positions of increasing responsibility in Baxter s Hemoglobin Therapeutics Program, ultimately being named project leader and vice president of R&D for the Second Generation Recombinant Hemoglobin Program. Dr. Burhop received his bachelor s degree in zoology from the University of Wisconsin- Milwaukee, a master of science degree in veterinary science/physiology from the University of Wisconsin-Madison and a doctorate in veterinary science/physiology, also from the University of Wisconsin-Madison. Prior to joining Baxter, Dr. Burhop completed an NIH Pulmonary Research Postdoctoral Fellowship at the Albany Medical College in Albany, New York.
Robert M. Davis is a corporate vice president and chief financial officer of Baxter International Inc., overseeing Baxter s global financial operations. Mr. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served as director of corporate financial planning. He held numerous positions, including tax counsel and assistant treasurer. As assistant treasurer, he had responsibility for overseeing the global treasury operations, including cash flow planning, capital markets, working capital management and affiliate funding worldwide. Mr. Davis earned his juris doctorate from Northwestern University School of Law and his master s degree from Northwestern University s Kellogg Graduate School of Management, after graduating from Miami University with a bachelor s degree in finance. Hartmut Ehrlich, M.D., is vice president, Global Research and Development for Baxter s BioScience business. Dr. Ehrlich joined Baxter in 1995 as medical director for its former Biotech business. He was named vice president, Global Clinical R&D in 2003 and assumed his current position in 2006. Dr. Ehrlich is based in Vienna, Austria. Dr. Ehrlich came to Baxter from Sandoz, now Novartis, and was based in Germany and Switzerland. He spent several years in basic protein research and patient care at the Department of Medicine, Hematology-Oncology of Indiana University and the Lilly Laboratories for Clinical Research in Indianapolis, Indiana. He also worked at the Department of Molecular Biology at the Central Laboratory of the Dutch Red Cross in Amsterdam, The Netherlands, and the Kerckhoff-Clinic of the Max-Planck-Foundation in Bad Nauheim, Germany. Dr. Ehrlich received his medical degree from the University of Giessen, Germany, and completed his doctorate at the Clinical Research Unit for Blood Coagulation and Thrombosis of the Max-Planck-Foundation. Dr. Ehrlich has authored and co-authored over 100 scientific publications and book chapters and is associated with the development and licensing of numerous biopharmaceutical products in the areas of hematology-oncology, immunology, critical care, hemophilia, vaccines and biosurgery. Camille I. Farhat is general manager of Baxter s Global Infusion Systems business unit within the Medication Delivery business. Before joining Baxter in February 2006, Mr. Farhat was vice president of business development at Medtronic and served earlier as vice president and global general manager of the company s Gastroenterology and Urology division. Prior to Medtronic, Mr. Farhat spent 13 years at General Electric (GE) with assignments in multiples businesses, countries and functions. Mr. Farhat earned a bachelor of science degree in international finance and accounting from Northeastern University. He also holds a master s degree in business administration from Harvard University and a master of arts degree in European Union Studies from the Institut National d Etudes Politiques de Paris.
John J. Greisch is a corporate vice president and president, International of Baxter International Inc. Mr. Greisch joined Baxter in 2002 as vice president of finance for Baxter s Renal business. He then assumed the role of vice president of finance and strategy for Baxter s BioScience business before being named president of that business. In 2004, he was named corporate vice president and chief financial officer. Prior to joining Baxter, Mr. Greisch was president and CEO of FleetPride Corporation, after completing a distinguished 11-year career at The Interlake Corporation, a diversified global manufacturing company, serving in a variety of roles, including chief financial officer, treasurer, president of Interlake s largest business and president of its European operations based in London. Mr. Greisch received a bachelor s degree in business administration from Miami University at Ohio and a master s degree in Management from Northwestern University s J.L. Kellogg Graduate School of Management. He is a certified public accountant and began his business career with PriceWaterhouseCoopers. Lawrence P. Guiheen is president, BioPharmaceuticals with responsibility for North America sales and marketing for plasma and recombinant therapies in Baxter s BioScience business. Mr. Guiheen joined Baxter in 1978 as a field sales representative in New York City. He has held a variety of positions in sales, marketing and operations in several business units of Baxter in the areas of oncology, diabetes, hematology and immunology. Prior to joining Baxter, Mr. Guiheen was with Alza Pharmaceuticals and earlier with Johnson & Johnson. Mr. Guiheen currently is on the board of the California Healthcare Institute (CHI) and has also held an industry board position in Plasma Protein Therapeutics Association (PPTA). Mr. Guiheen holds a bachelor of science degree in business administration from Rutgers University. David E. Holliday is vice president of marketing, Global Operations and Hemophilia in Baxter s BioScience business. He oversees global communications related to Baxter s hemophilia products, e-business, medical outcomes, pricing and reimbursement, hemophilia marketing and global medical affairs. Mr. Holliday came to Baxter UK in 2003 from Novartis, where he was business unit director for Transplantation, Tissue Engineering & Immunology. Prior to that he was with CIBA Pharmaceuticals. Mr. Holliday has a postgraduate degree in management studies from Kingston University in London.
Ronald K. Lloyd is vice president and general manager, BioTherapeutics and Regenerative Medicine in Baxter s BioScience business. He is responsible for the BioSurgery business and Cellular Therapies, which together form the foundation of the Regenerative Medicine franchise. He also is responsible for the strategy/portfolio functions of Baxter s biopharma products. Mr. Lloyd joined Baxter in 2003 as vice president, global marketing for BioPharmaceuticals. Prior to that he was vice president of marketing and business development, International Division for Abbott Laboratories. At Abbott, he also served as director, marketing and business development, cardiovascular and hospital products, and as business unit director for numerous therapeutic areas. Mr. Lloyd earned a master s degree in business administration from Carnegie-Mellon University, and a bachelor s degree from Westminster College. Bruce McGillivray is a corporate vice president of Baxter Healthcare Corporation and president of the company s global Renal business. In this position, he is responsible for the development and worldwide marketing of Baxter s peritoneal and hemodialysis products and services. Mr. McGillivray joined Baxter in 1980 as a territory manager for the Hospital Division in Canada, and throughout the years has held a succession of senior positions. He was named president of Baxter Canada in 1997 and in 2002 was named president of Renal Europe. In 2004, he was appointed to his current position as president of Baxter s global Renal business. Mr. McGillivray has a degree in economics from York University and a master's of business administration from the University of Toronto. Robert L. Parkinson, Jr. is chairman, chief executive officer and president of Baxter International Inc. Prior to joining Baxter in April 2004, Mr. Parkinson was dean of Loyola University Chicago s School of Business Administration and Graduate School of Business. Previously, Mr. Parkinson had a distinguished 25-year career at Abbott Laboratories, serving in a variety of domestic and international management and leadership positions. Mr. Parkinson joined Abbott in 1976 and held a number of marketing and management positions there before being named vice president of European operations in 1990, president of the chemical and agricultural division in 1993 and president of the international division responsible for pharmaceutical, hospital and nutritional products in 1995. In 1998 he became a member of its board of directors before being named president and chief operating officer of the company in 1999. Mr. Parkinson began his career in 1975 with American Hospital Supply Corporation. Mr. Parkinson is active in numerous business, healthcare industry and community organizations, including serving on the board of directors for Chicago-based Northwestern Memorial HealthCare and the Northwestern Memorial Foundation, as well as Loyola University Chicago s Board of Trustees. He earned both a bachelor s degree and a master s degree in business administration from Loyola University Chicago.
Sarah S. Prichard, M.D., is vice president, Global Medical/Clinical Affairs and Research for Baxter s Renal business. She oversees all scientific, clinical and medical affairs globally and advises the company on new and emerging trends in the management of patients with renal disease. She also provides input to product development teams in the design of new products and leads the design of clinical trials. Prior to joining Baxter in 2005, Dr. Prichard served as a member of Baxter s Scientific Advisory Board. She came to Baxter from McGill University, where she served as a professor of medicine, and the Royal Victoria Hospital, where she was senior physician and director of peritoneal dialysis. Dr. Prichard serves on the editorial board of Peritoneal Dialysis International and has served as president of the International Society of Peritoneal Dialysis and president of the Canadian Society of Nephrology. She also has served on the board of trustees and audit committee of Queen s University, as president and university representative for St. Mary s Hospital Board, and on the Governing Council of the Canadian Institutes of Health Research. Dr. Prichard received her medical degree from Queen s University in Kingston, Ontario, and nephrology training at McGill University. Norbert G. Riedel, Ph.D., is a corporate vice president and chief scientific officer of Baxter International Inc., having served in that capacity since 2001. Dr. Riedel joined Baxter in 1998 as president of the recombinant unit within Baxter's BioScience business. Prior to joining Baxter, he was head of worldwide biotechnology and worldwide core research functions at Hoechst Marion Roussel, now Sanofi-Aventis. Dr. Riedel received his Ph.D. in biochemistry from the University of Frankfurt in 1983. He was a postdoctoral fellow at Harvard University from 1984 to 1987, assistant professor and associate professor of medicine and biochemistry at Boston University School of Medicine from 1987 to 1991, and a visiting professor at Massachusetts Institute of Technology in 1992. He remains affiliated with Boston University as an adjunct professor and also serves as an adjunct professor of medicine at Northwestern University's Feinberg School of Medicine. Dr. Riedel serves on the board of directors of Oscient Pharmaceuticals Corporation and Medigene AG. He is a member of the board of directors of the Illinois Biotechnology Industry Organization and a member of the Advisory Board of Northwestern University's Kellogg School of Management Center for Biotechnology. Daniel Tassé is general manager of the newly formed Baxter Pharmaceuticals & Technologies (BPT) group within Baxter s Medication Delivery business. BPT is the result of the integration of the Anesthesia, Critical Care & Oncology business unit and the BioPharma Solutions business unit into a single pharmaceutical business. Prior to assuming his current position in January 2007, Mr. Tassé served as general manager of Baxter s Anesthesia, Critical Care & Oncology business unit. Mr. Tassé joined Baxter in 2004 from Glaxo SmithKline, where he was vice president and regional director for Australia and New Zealand. Prior to that, he held a number of marketing, sales management; healthcare services management and product development positions in the United States and Canada with Upjohn, SmithKlineBeecham and Glaxo SmithKline. Mr. Tassé received a bachelor s degree in biochemistry from the University of Montreal.
Rohit Vishnoi, Ph.D., is vice president, Product Development for Baxter s Renal business. He serves on Baxter s Innovation Council and Senior Technical Leadership team. Dr. Vishnoi joined Baxter in 1988 as a senior principal engineer in the Renal business. He was general manager of the Plasma, Advanced Component Collection and Whole Blood business units in the Baxter s Transfusion Therapies business from 1997 to 2003. Prior to his current position, he was VP of Technology Resources for Baxter. Dr. Vishnoi received his master s in management degree in marketing and finance from Northwestern University in Evanston, Illinois, and his doctorate from the Rensselaer Polytechnic Institute in Troy, New York. He received his undergraduate degree in Electrical Engineering from the Indian Institute of Technology in Kanpur, India. Dr. Vishnoi holds several design patents for Baxter products. His team won the 2005 MDEA Award for the ALYX Component Collection System as well as the 1995 R&D 100 Award for their involvement in the HOMECHOICE Peritoneal Dialysis System.